GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
The company secures funding to push its lead candidate towards US approval.
Prexasertib data worsen again, and biomarkers are up in the air.
Readout of the Pivot-006 trial is brought forward by nearly a year.
After Aktis's $318m flotation Eikon is a bigger proposition.
